Interpretation of Cytogenetic Results in Multiple Myeloma for Clinical Practice

Overview

Journal Blood Cancer J

Date 2015 Oct 31

PMID 26517360

Citations 101

Authors

A M Rajan

S V Rajkumar

Affiliations

Soon will be listed here.

Abstract

The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a challenging task. MM is characterized by several cytogenetic abnormalities that occur at various time points in the disease course. The interpretation of cytogenetic results in MM is complicated by the number and complexity of the abnormalities, the methods used to detect them and the disease stage at which they are detected. Specific cytogenetic abnormalities affect clinical presentation, progression of smoldering multiple myeloma (SMM) to MM, prognosis of MM and management strategies. The goal of this paper is to provide a review of how MM is classified into specific subtypes based on primary cytogenetic abnormalities and to provide a concise overview of how to interpret cytogenetic abnormalities based on the disease stage to aid clinical practice and patient management.

Citing Articles

Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma.

Mehra N, Sundaram S, Shah P, Rao A Curr Oncol Rep. 2025; 27(1):37-44.

PMID: 39776330 DOI: 10.1007/s11912-024-01623-5.

Advancements in Multiple Myeloma Research: High-Throughput Sequencing Technologies, Omics, and the Role of Artificial Intelligence.

Gutierrez-Gonzalez A, Del Hierro I, Cariaga-Martinez A Biology (Basel). 2024; 13(11).

PMID: 39596878 PMC: 11592186. DOI: 10.3390/biology13110923.

Evaluation of CD56 and CD117 Double-Positivity as a Predictor of Poor Prognosis in Multiple Myeloma Patients: A Retrospective Analysis.

Keski H, Merdan S, Zemheri I Turk J Haematol. 2024; 41(4):236-245.

PMID: 39377029 PMC: 11628754. DOI: 10.4274/tjh.galenos.2024.2024.0149.

Multiple myeloma in Latin America: A systematic review.

Hungria V, Pena C, Gomez-Almaguer D, Martinez-Cordero H, Schutz N, Blunk V EJHaem. 2024; 5(4):867-878.

PMID: 39157594 PMC: 11327730. DOI: 10.1002/jha2.905.

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Rajkumar S Am J Hematol. 2024; 99(9):1802-1824.

PMID: 38943315 PMC: 11404783. DOI: 10.1002/ajh.27422.

References

Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole D . Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995; 86(11):4250-6. View

Bergsagel P, Chesi M, Nardini E, Brents L, Kirby S, Kuehl W . Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A. 1996; 93(24):13931-6. PMC: 19472. DOI: 10.1073/pnas.93.24.13931. View

Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp M, Harousseau J . 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res. 1999; 59(18):4546-50. View

Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell.... Blood. 2006; 108(5):1724-32. PMC: 1895503. DOI: 10.1182/blood-2006-03-009910. View

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M . Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007; 138(2):176-85. DOI: 10.1111/j.1365-2141.2007.06639.x. View

Qazilbash M, Saliba R, Ahmed B, Parikh G, Mendoza F, Ashraf N . Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007; 13(9):1066-72. DOI: 10.1016/j.bbmt.2007.05.014. View

Kumar S, Mikhael J, Buadi F, Dingli D, Dispenzieri A, Fonseca R . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84(12):1095-110. PMC: 2787395. DOI: 10.4065/mcp.2009.0603. View

Fonseca R, Bergsagel P, Drach J, Shaughnessy J, Gutierrez N, Stewart A . International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-21. PMC: 2964268. DOI: 10.1038/leu.2009.174. View

Avet-Loiseau H, Soulier J, Fermand J, Yakoub-Agha I, Attal M, Hulin C . Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 2010; 24(3):623-8. DOI: 10.1038/leu.2009.273. View

10.

Nair B, van Rhee F, Shaughnessy Jr J, Anaissie E, Szymonifka J, Hoering A . Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010; 115(21):4168-73. PMC: 2879104. DOI: 10.1182/blood-2009-11-255620. View

11.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A . Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010; 95(7):1150-7. PMC: 2895040. DOI: 10.3324/haematol.2009.016436. View

12.

Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M . Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia. 2010; 24(8):1498-505. PMC: 3558529. DOI: 10.1038/leu.2010.128. View

13.

Cavo M, Tacchetti P, Patriarca F, Petrucci M, Pantani L, Galli M . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised.... Lancet. 2010; 376(9758):2075-85. DOI: 10.1016/S0140-6736(10)61424-9. View

14.

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

15.

Herve A, Florence M, Philippe M, Michel A, Thierry F, Kenneth A . Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol. 2011; 29(14):1893-7. DOI: 10.1200/JCO.2010.32.8435. View

16.

Rajkumar S . Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011; 8(8):479-91. PMC: 3773461. DOI: 10.1038/nrclinonc.2011.63. View

17.

Rajkumar S . Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011; 87(1):78-88. PMC: 3629949. DOI: 10.1002/ajh.22237. View

18.

Boyd K, Ross F, Walker B, Wardell C, Tapper W, Chiecchio L . Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011; 17(24):7776-84. PMC: 5751883. DOI: 10.1158/1078-0432.CCR-11-1791. View

19.

Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011; 26(1):149-57. PMC: 4109061. DOI: 10.1038/leu.2011.196. View

20.

Neben K, Lokhorst H, Jauch A, Bertsch U, Hielscher T, van der Holt B . Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2011; 119(4):940-8. DOI: 10.1182/blood-2011-09-379164. View